Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · IEX Real-Time Price · USD
9.85
+0.05 (0.51%)
Jul 22, 2024, 10:17 AM EDT - Market open
Travere Therapeutics Employees
Travere Therapeutics had 380 employees as of December 31, 2023. The number of employees decreased by 82 or -17.75% compared to the previous year.
Employees
380
Change (1Y)
-82
Growth (1Y)
-17.75%
Revenue / Employee
$482,171
Profits / Employee
-$424,024
Market Cap
754.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Embecta | 2,200 |
Phibro Animal Health | 1,920 |
Sage Therapeutics | 487 |
Evolus | 273 |
OrthoPediatrics | 247 |
Pliant Therapeutics | 158 |
4D Molecular Therapeutics | 147 |
Nuvation Bio | 51 |
TVTX News
- 13 days ago - Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference - GlobeNewsWire
- 5 weeks ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Travere Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Report First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - GlobeNewsWire
- 3 months ago - CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - PRNewsWire